Pricing Log in Create free account

Lexicon Pharmaceuticals, Inc. (LXRX) vs Solid Biosciences Inc. (SLDB)

Lexicon Pharmaceuticals, Inc. and Solid Biosciences Inc. are both Biotechnology companies. Lexicon Pharmaceuticals, Inc. and Solid Biosciences Inc. are of similar size ($716.4M and $662.7M). Solid Biosciences Inc. has the higher net margin (0.00% vs −161.8%) and the higher return on invested capital (0.00% vs −109.1%). Across the 16 metrics below, Lexicon Pharmaceuticals, Inc. leads on 9 and Solid Biosciences Inc. on 7.

Valuation

Metric LXRX SLDB Biotechnology median
P/E n/m n/m 10.60
P/S 20.67 88.22 9.40
P/B 4.86 2.90 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 17.38 57.17 9.02
Earnings yield (8.05%) (27.20%) (32.88%)
Free cash flow yield (6.31%) (20.18%) (23.13%)

Profitability

Metric LXRX SLDB Biotechnology median
Gross margin 98.89% 0.00% 68.51%
Operating margin (147.42%) 0.00% 0.00%
Net margin (161.80%) 0.00% 0.00%
Free cash flow margin (127.76%) 0.00% 0.00%
Return on equity (43.91%) (76.87%) (51.96%)
Return on assets (27.84%) (64.86%) (46.06%)
Return on invested capital (109.13%) 0.00% 0.00%

Growth

Metric LXRX SLDB Biotechnology median
Revenue growth (TTM) (45.62%) — 6.76%
EPS growth (last fiscal year) 77.78% 34.97% 29.88%
Revenue growth, 5-year CAGR 15.72% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LXRX SLDB Biotechnology median
Debt to equity 0.32 0.00 0.00
Current ratio 10.63 11.99 4.97
Net debt to EBITDA 0.91 1.05 1.01

Dividend

Metric LXRX SLDB Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric LXRX SLDB Biotechnology median
Market cap 716.37m 662.65m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack